Bleeding Disorder Testing Market Size
Bleeding Disorder Testing Market size was valued at around USD 88 million in 2022 and is projected to register around 7% CAGR between 2023 and 2032. Increasing prevalence of hemophilia along with other bleeding disorders across the globe will fuel the market growth.

The bleeding disorder testing has improved substantially over the recent years, pertaining to the emergence of novel & accurate diagnostics. Also, in order to promote awareness regarding this disorder & associated diagnosis, several federal agencies & public associations are coming forward to increase awareness. Moreover, in recent years, awareness associated with the significance of early-stage diagnosis of bleeding disorders and its potential benefit is rising significantly in the European countries, thereby accelerating the demand for bleeding disorder testing.
Bleeding disorder testing involves various laboratory tests & procedures that assists in diagnosing and monitor bleeding disorders. These testing kits and analyzing instruments are extensively used in the diagnosis of bleeding disorders that include hemophilia, von Willebrand disease, idiopathic thrombocytopenic purpura, and platelet function disorders among others. These tests help identify the underlying cause of abnormal bleeding or bruising, evaluate the severity of the disorder, and offer guidance for appropriate treatment.
Bleeding Disorder Testing Market Report Attributes
Report Attribute |
Details |
Base Year | 2022 |
---|
Bleeding Disorder Testing Market Size in 2022 | USD 88.3 Million |
---|
Forecast Period | 2023 to 2032 |
---|
Forecast Period 2023 to 2032 CAGR | 7% |
---|
2032 Value Projection | USD 169.6 Million |
---|
Historical Data for | 2018 to 2022 |
---|
No. of Pages | 200 |
---|
Tables, Charts & Figures | 369 |
Segments covered | Product, Indication, End-use and Region |
---|
Growth Drivers | - Product, Indication, End-use and Region
- Increasing prevalence of blood disorders
- Technological Advancements
- Supportive government initiatives
- Recent product approvals
|
---|
Pitfalls & Challenges | - Lack of skilled professionals
|
---|
Unfortunately, the lack of skilled professionals to perform bleeding disorder tests could be a roadblock for the market's growth. These tests require specific expertise to ensure accurate diagnoses and guide the best treatments. In regions with limited healthcare resources and training, the shortage of skilled professionals can slow down the rate of testing for bleeding disorders. This hinders the market's potential growth because testing involves multiple steps, including sample collection and analysis, each requiring precision to prevent misleading results. So, the availability of well-trained professionals is crucial for the industry's expansion.
Impact of COVID-19 Pandemic
The COVID-19 pandemic put a damper on the testing market for bleeding disorders in early 2020. People were understandably concerned about getting other medical treatments at healthcare facilities, especially since COVID-19 was spreading rapidly and killing a lot of people. The fear of infection made people put off getting tested for bleeding disorders. Plus, supply chains were disrupted because of travel restrictions, making it harder to get testing equipment and supplies. All these factors hurt the revenue of companies in the bleeding disorder testing industry during 2020. But things are starting to look up. More and more people are getting vaccinated against COVID-19, and the number of cases is going down. This means people are more willing to get other medical tests done, including tests for bleeding disorders. Plus, the government and companies in the industry are working together to make testing more accessible. So, the future is looking brighter for the bleeding disorder testing market.
Bleeding Disorder Testing Market Trends
As more people develop bleeding disorders like hemophilia and platelet problems, there will be a growing need for quick and accurate ways to diagnose them, leading to growth in the industry. This is because disorders like these are becoming more common. For example, according to the National Centers for Biotechnology Information, hemophilia A affects about 1 in 5000 boys, making it the most common clotting disorder present at birth. Meanwhile, hemophilia B is a genetic disorder that affects about 1 in 30,000 baby boys born in the United States. So many people being affected will likely lead to a big market, as more patients will need accurate tests to help them.
Furthermore, patients that undergo diagnosis & are detected with bleeding disorders in the early stage are likely to develop fewer co-morbid conditions and have a lower risk of severe bleeding. Thus, the ever-increasing patient population has significantly increased demand for precise diagnostics, thereby driving the adoption of bleeding disorder testing.
Bleeding Disorder Testing Market Analysis
When it comes to the bleeding disorder testing market, you can break it down into two main categoriesstuff you need to do the tests (reagents and consumables) and the machines that do the tests (instruments). In 2022, the reagents and consumables part of the market was the biggest boss, raking in over 58% of the cash. This is no surprise, considering all the fancy diagnostic kits, new products, and tech upgrades that have been popping up in recent years. For example, back in March 2020, Siemens Healthineers came out with their Sysmex CS-2500 System and its sidekick, the PS-2500 Automated Sample Preparation Module. This sweet setup is like a robot for blood tests, making them faster and more accurate. When companies launch products like this that make testing better and more reliable, it's no wonder the market keeps growing like a weed.

Based on indication, the bleeding disorder testing market is segmented as hemophilia A, hemophilia B, von Willebrand disease, idiopathic thrombocytopenic purpura, and others. The hemophilia A segment held the largest revenue share in 2022 and is expected to significantly expand at a 7.5% CAGR from 2023-2032. This significant segmental share is due to the higher prevalence of hemophilia A, significant products that cater to the condition, and surging disease awareness among the population.
When it comes to testing for bleeding disorders, different places handle this task, such as hospitals and clinics, specialized diagnostic centers, and other facilities. Diagnostic centers have been doing particularly well in this field, bringing in over $38 million in 2022 alone. And they're expected to keep growing at a good clip in the coming years. Why? Because more and more people are becoming aware of serious bleeding diseases, and diagnostic centers are offering specialized and effective tests for them. Plus, these centers are expanding their reach and setting up more locations, so they can provide these important tests to people all over the country.
Additionally, the use of advanced screening mechanisms at diagnostic laboratories drives patient preference. Thus, considering the above-mentioned factors, the increasing testing at diagnostic laboratories will drive the market demand during the estimation timeframe.
U.S. dominated the North America bleeding disorder testing market with a dominant revenue share in 2022 and is anticipated to reach more than USD 54 million by 2032. This high revenue surge is majorly attributed to multiple variables such as the facilitative initiatives, high disease prevalence, new product launches along with the presence of established manufacturers. The increasing awareness associated with technologically novel products and the surging target population pool is also contributing to the market revenue growth.
Bleeding Disorder Testing Market Share
Some of the major players operating in the bleeding disorder testing industry are
- Siemens Healthineers
- F Hoffmann La Roche AG
- Bio-Rad Laboratories
- Thermo Fischer Scientific Inc
- Cephied (Danaher Corporation)
- Abbott Laboratories Inc.
These leading market players are implementing advanced technologies to cater to the large unmet needs of the consumers.
Bleeding Disorder Testing Industry News
- In October 2022, Siemens Healthineers announced the introduction of its INNOVANCE VWF Ac assay, a fully automated assay for use on the Siemens Healthineers BCS XP System, as well as on the Sysmex CS-2500 and CS-5100 hemostasis analyzers. The assay's VWFGPIbM technology allows for a more accurate functional assessment of VWF activity with greater precision and heightened sensitivity, and the ability to detect VWF variants that otherwise might be missed compared to other commercially available VWF assay technologies. This launch helped the company to introduce innovative products, further offering a competitive edge.
Bleeding disorder testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD and Units from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Product
- Reagents & Consumables
- Instruments
By Indication
- Hemophilia A
- Hemophilia B
- Von Willebrand Disease
- Idiopathic Thrombocytopenic Purpura
- Others
By End-use
- Hospitals and clinics
- Diagnostic Centers
- Others
The above information is provided for the following regions and countries
- North America
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Switzerland
- The Netherlands
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Indonesia
- Philippines
- Vietnam
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Chile
- Peru
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Israel
- Egypt
- Turkey